Updated 06:11 GMT, 17 Nov 2026 SPX 7,416.59 -1.92% NDX 27,197.15 -2.67% VIX 22.91 +18.70% GOLD 3,883.00 +0.78% CL 84.99 -0.85% BTC 64,683.65 -0.95%
NAS100 27,197 −2.67% S&P 7,417 −1.92% GOLD $3,883 +0.78% BTC $64,684 −0.95% VIX 22.91 +18.70% latest tape · as of 06:11 UTC
The Screen · Healthcare · Medical Care Facilities

Oncology Institute Inc

TOI · NASDAQ · USD · Market cap $535M · 641 employees

The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States.

FAIL · Does not pass the screen
6.20 USD

Price as of 11 Aug 2026Daily close, not a live quoteLast reviewed 98 days ago

Screened 2026-08-11 · the tape above runs as of 06:11 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price6.20 USD at the 11 Aug 2026 close
  • Fair valueUnder review: its inputs are 96 days old.
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed11 Aug 2026 (98 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-08-11).

Current read
Markup ?
Screened · screened 2026-08-11
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price6.20 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-08-14Read Markup5.35+15.9% to today ✓Accumulation gives way to Markup
2026-07-02Read Accumulation5.31+16.8% to today ✓First review on file: Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Oncology Institute Inc holds its Markup at $6.20. Consolidating, no directional conviction, held for 7 days.

As held on the ledger · 2026-08-11
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 7 days
Price at the screen$6.20
ValuationN/A trailing · -33.44 forward price to earnings
Values screenFAIL · score 70.0
Beta0.39
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 62.97% Below 33% Interest-bearing debt is 63.0% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 56.22% Below 49% Money owed to the company is 56.2% of assets, above the 49% limit. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Oncology Institute's business is in a permissible area, but its interest-bearing debt is about 63% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when TOI's ethical verdict changes

Today TOI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Its inputs are 96 days old. We show no fair value, margin of safety or value read built on it until the review clears.

How a fair value is estimated: discounted cash flow (DCF).

The Street's Range
7.00Street low 8.00Street average 10.00Street high 6.20Price

Third-party analyst targets: 5 covering, consensus Strong Buy. The average target sits +29% from the screen price.

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-08-11 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-33.4x
EPS, trailing-0.35
EPS, forward-0.16
Revenue growth+41.2%growing very fast
Profit margin-8.0%currently unprofitable
FCF yield-2.86%
Current ratio1.47adequate liquidity, worth monitoring
Beta0.39barely tracks the market's swings
Short interest, float0.08%
52-week range2.32 - 6.67
MoatNONE
Market cap$535M
Employees641

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

TOI trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-15 Markup $6.20 +0.0% Entry 9

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 67% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (4 analysts) rates it strong buy, with a mean price target of $8.

2026-11-04 Markup $6.20 +0.0% Entry 8

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 67% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (4 analysts) rates it strong buy, with a mean price target of $8.

2026-10-23 Markup $6.20 +0.0% Entry 7

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 67% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (4 analysts) rates it strong buy, with a mean price target of $8.

2026-10-02 Markup $6.20 +15.9% Entry 6

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (4 analysts) rates it strong buy, with a mean price target of $8.

2026-09-15 Markup $5.35 +0.0% Entry 5

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (4 analysts) rates it strong buy, with a mean price target of $8.

2026-08-14 Markup · changed $5.35 +0.8% Entry 4

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (4 analysts) rates it strong buy, with a mean price target of $8.

2026-07-18 Accumulation $5.31 +0.0% Entry 3

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (4 analysts) rates it strong buy, with a mean price target of $8.

2026-07-03 Accumulation $5.31 +0.0% Entry 2

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.

2026-07-02 Accumulation $5.31 Entry 1

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in TOI's Space

Screened names in the same industry · explore each on its own page.

The Political Ledger · Congressional Disclosures
Disclosures naming TOI
DatePoliticianPartyTypeAmount
2026-09-04 Jonathan Jackson Democrat sell 1K–15K
2026-09-04 Jonathan Jackson Democrat sell 1K–15K
2026-09-04 Jonathan Jackson Democrat sell 1K–15K
2026-09-04 Jonathan Jackson Democrat sell 1K–15K
2025-11-21 John Boozman Republican sell 1K–15K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $4.01 +16.7% · $1,167 +16.7%
2 months $3.08 +52.0% · $1,520 +52.0%
3 months $2.62 +78.6% · $1,786 +78.6%
6 months $3.76 +24.5% · $1,245 +24.5%
1 year $2.66 +75.9% · $1,759 +75.9%
2 years $0.45 +940.0% · $10,400 +940.0%
3 years $0.62 +654.8% · $7,548 +654.8%
5 years $10.15 -53.9% · $461 -53.9%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever TOI does next, these words stay.

Oncology Institute Inc · TOI · Markup · $6.20
Recorded 2026-08-11 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.